XBiotech Inc. is a biopharmaceutical company developing True Human monoclonal antibodies to treat diseases such as inflammatory conditions, infectious diseases, cardiovascular diseases, and cancer. These antibodies are derived from human donors with natural immune responses. The company focuses on therapies that block interleukin-1 alpha (IL-1a), which is involved in processes like tissue breakdown, angiogenesis, tumor stroma remodeling, blood clot formation, malaise, muscle wasting, and inflammation. XBiotech's products include Natrunix, a clinical-stage therapeutic for MRSA, and several pre-clinical-stage therapeutics, including an oral antibody for C. difficile colon infection. The XBIT average annual return since 2015 is shown above.
The Average Annual Return on the XBIT average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether XBIT average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the XBIT average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free XBIT Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
